MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Intra-Cellular Therapies Inc

Fermé

SecteurSoins de santé

131.89 -0.02

Résumé

Variation du prix de l'action

24h

Actuel

Min

131.89

Max

131.89

Chiffres clés

By Trading Economics

Revenu

9.4M

-17M

Ventes

24M

199M

BPA

-0.16

Marge bénéficiaire

-8.475

Employés

860

EBITDA

9.8M

-29M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

-0.79% downside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.8B

14B

Ouverture précédente

131.91

Clôture précédente

131.89

Sentiment de l'Actualité

By Acuity

51%

49%

320 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Intra-Cellular Therapies Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 janv. 2025, 12:11 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson to Acquire Intra-Cellular in $14.6 Billion Deal

13 janv. 2025, 11:40 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson in Talks to Acquire Intra-Cellular Therapies, Says Bloomberg

14 mars 2025, 09:30 UTC

Actualités

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

22 janv. 2025, 14:09 UTC

Actualités
Résultats

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22 janv. 2025, 11:22 UTC

Actualités
Résultats

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

13 janv. 2025, 21:20 UTC

Acquisitions, Fusions, Rachats

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug -- IBD

13 janv. 2025, 20:12 UTC

Actualités
Acquisitions, Fusions, Rachats

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- Update

13 janv. 2025, 16:18 UTC

Actualités
Acquisitions, Fusions, Rachats

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- WSJ

13 janv. 2025, 15:57 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal -- Barrons.com

13 janv. 2025, 14:10 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal -- IBD

13 janv. 2025, 12:25 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 janv. 2025, 11:57 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson Confirms $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 janv. 2025, 11:56 UTC

Actualités
Acquisitions, Fusions, Rachats

Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal

13 janv. 2025, 11:45 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson: Intra-Cellular's Clinical-Stage Pipeline Has Best-In-Disease Potential in Generalized Anxiety Disorder, Alzheimer's Treatments >JNJ

13 janv. 2025, 11:43 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson: Caplyta Solidifies Sales Above Analyst Expectations Through Remainder of Decade>JNJ

13 janv. 2025, 11:43 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson: Caplyta Has Potential of Over $5 Billion in Peak Yr Sales >JNJ

13 janv. 2025, 11:42 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson Purchases Intra-Cellular for $132/Shr in Cash, or About $14.6B >JNJ

13 janv. 2025, 11:41 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson: SNDA Submitted to FDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder >JNJ

13 janv. 2025, 11:40 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson: Acquisition Includes CaplytaTreatment for Bipolar I and II Depression, Schizophrenia >JNJ

13 janv. 2025, 11:34 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson: Deal Adds Intra-Cellular's Caplyta Depression Drug >JNJ ITCI

13 janv. 2025, 11:32 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson: To Maintain Strong Balance Sheet, Continue to Support Capital-Allocation Priorities >JNJ

13 janv. 2025, 11:32 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson To Fund Transaction With Cash on Hand, Debt >JNJ ITCI

13 janv. 2025, 11:31 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson to Buy Intra-Cellular Therapies for About $14.6 Billion >JNJ ITCI

13 janv. 2025, 11:31 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson to Buy Intra-Cellular Therapies for $132/Share in Cash >JNJ ITCI

13 janv. 2025, 11:30 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson Strengthens Neuroscience Leadership With Acquisition Of Intra-Cellular Therapies, Inc. >JNJ ITCI

13 janv. 2025, 10:55 UTC

Acquisitions, Fusions, Rachats

This Stock Is Soaring Amid Johnson & Johnson Takeover Report -- Barrons.com

13 janv. 2025, 10:41 UTC

Acquisitions, Fusions, Rachats

This Stock Is Soaring Amid J&J Takeover Report. What to Know. -- Barrons.com

Comparaison

Variation de prix

Intra-Cellular Therapies Inc prévision

Objectif de Prix

By TipRanks

-0.79% baisse

Prévisions sur 12 Mois

Moyen 130.83 USD  -0.79%

Haut 132 USD

Bas 118 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

13 ratings

4

Achat

9

Maintien

0

Vente

Score Technique

By Trading Central

131.45 / 131.87Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

No Evidence

Long Terme

No Evidence

Sentiment

By Acuity

320 / 386Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.